11 registrations that name palmitoylethanolamide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 11 registrations
Status
Phase
All 11 registrations
RecruitingNCT07315516
Sleep and Stress Study
Phase 2
RDC Clinical Pty Ltd
About 240 people
Started Apr 7, 2026
In plain words A Phase 2 study of palmitoylethanolamide in people 18 and older, run by RDC Clinical Pty Ltd. It plans to enroll about 240 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sleep Disorder (Disorder); Stress; Anxiety.
Generally healthy adults aged 18 and over.
Able to provide informed consent.
Score of at least 14 on the Perceived Stress Scale (PSS).
Those with a sleep complaint with a frequency of at least 2 times per week(1)
4 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn if natural supplements (lavender oil, PEA, and OEA) work to improve sleep and reduce stress in adults with moderate stress levels and sleep difficulties. It will also learn about the safety of these natural supplements. The full summary is on the listing.
Where, as registered
No US site; Australia (1).
RecruitingNCT07772141
Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain
No phase
Beni-Suef University
About 106 people
Started Jan 1, 2026
In plain words A study of palmitoylethanolamide in people 18 to 65, run by Beni-Suef University. It plans to enroll about 106 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Chronic Low-back Pain.
With chronic pain (more than 3 months)
Patients with NRS (4 -7)
MRI evidence of disc protrusion or prolapse limited to one or two lumbar discs, without extensive multi-level pathology
Diagnosed clinically with low back pain due to disc disease.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Palmitoylethanolamide
Registered summary
Low back pain (LBP) is a public and occupational health problem that is a major professional, economic and social burden. Up to 84% of the general population will experience an episode of LBP during its life time, and recurrence rates are high. Acute LBP is the second reason for consultations in general medicine, and chronic LBP is the eighth. One in five LBP episodes result in sick leave. LBP represents 30% of sick leaves that are longer than 6 months, and 20% of work accidents. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07028528
Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy
Phase 2
RDC Clinical Pty Ltd
About 80 people
Started Jul 1, 2025
In plain words A Phase 2 study of palmitoylethanolamide in people 18 to 75, run by RDC Clinical Pty Ltd. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Diabetic Peripheral Neuropathy.
Adults aged 18-75 years.
Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and/or insulin for diabetes (type 1 or 2).
Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS).
Able to provide informed consent.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Levagen+; Placebo
Registered summary
The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN. Participants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.
Where, as registered
No US site; Australia (1).
RecruitingNCT07609810
Palmitoylethanolamide in Ulcerative Colitis
No phase
Ain Shams University
About 60 people
Starts Aug 15, 2026 (estimated)
In plain words A study of palmitoylethanolamide in people 18 to 65, run by Ain Shams University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Ulcerative Colitis (UC).
Confirmed diagnosis of ulcerative colitis (UC) by established clinical and endoscopic criteria.
Active mild-to-moderate UC patients defined by a SCCAI score ≥ 5 and < 12 at screening not responding to 5-aminosalicylates (5-ASA) defined as persistent rectal bleeding beyond 2 weeks or failure to achieve sustained symptom relief after…
The exclusion criteria are on the listing.
What it tests, as registered
Palmitoylethanolamide (PEA); Placebo
Registered summary
Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07689214
Normast3 for Adults With Diabetic Polyneuropathy
No phase
University of Roma La Sapienza
About 40 people
Started Jul 17, 2024
In plain words A study of palmitoylethanolamide in people 18 to 80, run by University of Roma La Sapienza. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Diabete Type 2.
What it tests, as registered
Normast® 3 - a food for special medical purposes (FSMP) containing co-micronized palmitoylethanolamide (PEA) with rutin and hydroxytyrosol. It is designed to support the management of diabetic polyneu; Placebo
Registered summary
The goal of this clinical trial is to find out if a new supplement called Normast® 3 can help reduce nerve pain and improve nerve function in adults with diabetic polyneuropathy (DPN). DPN is a common complication of diabetes that damages nerves, often causing burning, tingling, or stabbing pain, as well as problems with the autonomic nervous system, which controls things like sweating and heart rate. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT06187090
The Supplementation Therapy in Autism and Response to Treatment Study
No phase
University of Udine
About 20 people
Started Sep 1, 2023
In plain words A study of palmitoylethanolamide in people 18 to 35, run by University of Udine. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 35. Conditions: Autism; Autism Spectrum Disorder; Autism Spectrum Disorder High-Functioning; Asperger Syndrome; Depressive Symptoms; Anxiety State.
Individuals diagnosed with Level 1 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5);
Aged 18-35 years;
To be able to understand and communicate in Italian;
To be able to give informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form
Registered summary
In addition to the "core" symptoms of ASD (i.e., impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests), it is estimated that up to 70% of autistic people present at least one comorbid psychiatric disorder, leading to a deterioration in quality of life, a greater demand for support and worse prognosis and outcome. Anxiety and depressive symptoms would seem to be more present in individuals with Level 1 ASD, requiring their prioritisation against core symptoms. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT07359534
Training Health Recovery and Improvement Via Levagen+® Evaluation
No phase
University of Westminster
About 20 people
Started Mar 10, 2025
In plain words A study of palmitoylethanolamide in people 18 to 50, run by University of Westminster. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 50; healthy volunteers accepted. Conditions: Exercise Recovery.
Healthy subjects
Males and females (18-50 years of age)
Trained cyclists/triathletes indicated by:
Minimum functional threshold power (FTP, an indication of the highest average power output a cyclist can maintain for 60 minutes) of 2.9W/kg for males and 2.5W/kg for females
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Levagen+® Palmitoylethanolamide (PEA); Placebo
Registered summary
INTRODUCTION: Sports supplements and ergogenic aids are widely used for performance enhancement in recreational and professional sports. Athletes undergo intense training to improve their cardiorespiratory and muscular systems, aiming for positive adaptations. However, intensified training without appropriate dietary support can pose risks such as inadequate muscle recovery, weakened immune function, and reduced sleep quality, leading to increased susceptibility to illness and heightened physiological and psychological stress. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (1).
Not yet recruitingNCT07316660
Palmitoylethanolamide vs Ibuprofen for Pain After ESWL
No phase
Benha University
About 120 people
Starts Jan 1, 2026 (estimated)
In plain words A study of palmitoylethanolamide in people 18 to 65, run by Benha University. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Pain After Extracorporeal Shock Wave Lithotripsy; Palmitoylethanolamide.
Age 18-65 years
ASA I or II
Undergoing elective ESWL for renal or upper ureteric calculi
Expected discharge same day or within 24 hours (outpatient ESWL).
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Palmitoylethanolamide (PEA); Ibuprofen (Brufen®)
Registered summary
Pain after extracorporeal shock wave lithotripsy (ESWL), a non-surgical procedure used to treat kidney stones, is common and is usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, NSAIDs may cause side effects in some patients, including stomach irritation and kidney problems. Palmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07681063
Palmitoylethanolamide/Luteolin Supplementation in Older Adults Undergoing Cardiac Surgery
No phase
Fondazione IRCCS San Gerardo dei Tintori
About 100 people
Starts Jun 2026 (estimated)
In plain words A study of palmitoylethanolamide in people 65 and older, run by Fondazione IRCCS San Gerardo dei Tintori. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older. Conditions: Postoperative Cognitive Dysfunction.
Age ≥ 65 years
Both genders
Undergoing elective aortic or mitral valve replacement/reconstruction with or without coronary artery bypass grafting (CABG), at the Cardiac Surgery Unit of IRCCS San Gerardo dei Tintori Foundation (Monza, Italy)
Prognosis quoad vitam ≥ 3 months
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
co-ultramicronized Palmitoylethanolamide + Luteolin (700 mg + 70 mg in 10 ml); Standard of Care
Registered summary
Postoperative Cognitive Dysfunction (POCD) is a common complication after surgery, particularly among older adults. It is characterized by cognitive impairment, reduced functional independence, and decreased quality of life. Growing evidence suggests that neuroinflammation plays a relevant role in POCD development and persistence. Palmitoylethanolamide (PEA) is an endogenous lipid mediator involved in the regulation of neuroinflammatory processes through the modulation of non-neuronal cells, while luteolin is a flavonoid with well-known antioxidant properties. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT07680101
Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration.
No phase
Universita di Verona
About 80 people
Starts Jun 2026 (estimated)
In plain words A study of palmitoylethanolamide in people 40 and older, run by Universita di Verona. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: Degenerative Joint Disease of Knee; Rheumatoid Arthritis.
Age ≥ 40 years
Male or female
Diagnosis of unilateral or bilateral knee joint degeneration due to osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III
Duration of knee pain ≥ 6 months
4 more inclusion criteria and the exclusion criteria are on the listing.
Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT06777680
Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke
No phase
Ospedali Riuniti Trieste
About 60 people
Starts Jan 2025 (estimated)
In plain words A study of palmitoylethanolamide in people 60 and older, run by Ospedali Riuniti Trieste. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older. Conditions: Acute Ischemic Stroke AIS.
age ≥ 60 years
both genders
first acute ischemic stroke in the middle cerebral artery area confirmed by angio-CT and CTP, eligible for mechanical thrombectomy according to national guidelines
NIHSS > 6
2 more inclusion criteria and the exclusion criteria are on the listing.
Acute ischemic stroke is caused by reduced blood supply to the brain associated with neuroinflammation. This mechanism contributes to acute neuronal death and persists even after reopening of the closed vessel, with consequent limitation of clinical and functional improvement. Experimental and clinical evidence demonstrated the anti-inflammatory and neuroprotective effect of micronized and ultramicronized Palmitoylethanolamide (PEA). The full summary is on the listing.
Where, as registered
No US site; Italy (1).
ClinicalTrials.gov lists 19 open registrations for this search, including ones where palmitoylethanolamide is not a study arm or that are past the 11 we keep. Search them on ClinicalTrials.gov (opens in new tab).